Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—ACE inhibitor therapy is widely used in lower-risk patients with type 2 diabetes to reduce mortality, despite limited evidence to support this clinical strategy. The aim of this study was to evaluate the association between ACE inhibitor use and mortality in patients with diabetes and no cardiovascular disease. RESEARCH DESIGN AND SETTINGS—Using the Saskatchewan health databases, 12,272 new users of oral hypoglycemic agents were identified between the years of 1991 and 1996. We excluded 3,202 subjects with previous cardiovascular disease. Of the remaining subjects, 1,187 “new users” of ACE inhibitors were identified (ACE inhibitor cohort). Subjects not receiving ACE inhibitor therapy throughout the follow-up period served as the control cohort (n = 4,989). Subjects were prospectively followed until death or the end of 1999. Multivariate Cox proportional hazards models were used to assess differences in all-cause and cardiovascular-related mortality between cohort groups. RESULTS—Subjects were 60.7 ± 13.7 years old, 43.6% female, and were followed for an average of 5.3 ± 2.1 years. Mean duration of ACE inhibitor therapy was 3.6 ± 1.8 years. We observed significantly fewer deaths in the ACE inhibitor group (102 [8.6%]) compared with the control cohort (853 [17.1%]), with an adjusted hazard ratio (HR) and 95% CI of 0.49 (0.40–0.61) (P < 0.001). Cardiovascular-related mortality was also reduced (40 [3.4%] vs. 261 [5.2%], adjusted HR, 0.63 [0.44–0.90]; P = 0.012). CONCLUSIONS—The use of ACE inhibitors was associated with a significant reduction in all-cause and cardiovascular-related mortality in a broad spectrum of patients with type 2 diabetes and no cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
Self-citation
Cited by
Preventing Microalbuminuria in Type 2 Diabetes
Ruggenenti, P., Fassi, A., Ilieva, A. P., Bruno, S., Iliev, I. P., Brusegan, V., Rubis, N., Gherardi, G., Arnoldi, F., Ganeva, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042167 · Cited by 1,020
The Impact of Comorbid Chronic Conditions on Diabetes Care
Piette, J. D., & Kerr, E. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-2078 · Cited by 731
Type 2 diabetes mellitus in older adults: clinical considerations and management
Bellary, S., Kyrou, I., Brown, J. E., & Bailey, C. J. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00512-2 · Cited by 639
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure
Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., & Johnson, J. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2345 · Cited by 419
Self-citationThe RAAS in the pathogenesis and treatment of diabetic nephropathy
Ruggenenti, P., Cravedi, P., & Remuzzi, G. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.58 · Cited by 319
Metadata
- Authors
- Eurich, D. T., Majumdar, S. R., Tsuyuki, R. T., & Johnson, J. A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2004-06-01
- Volume
- 27
- Issue
- 6
- Pages
- 1330-1334
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2158388227
- Cited by
- 65
- References
- 3
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/diacare.27.6.1330
- The paper
- Eurich, D. T., Majumdar, S. R., Tsuyuki, R. T., & Johnson, J. A. (2004). Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/diacare.27.6.1330
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.